Archives of Gynecology and Obstetrics

, Volume 298, Issue 4, pp 689–695 | Cite as

Neonatal outcome in gestational-diabetic mothers treated with antenatal corticosteroids delivering at the late preterm and term

  • Eyal KrispinEmail author
  • Alyssa Hochberg
  • Rony Chen
  • Arnon Wiznitzer
  • Eran Hadar
  • Adi Borovich
Maternal-Fetal Medicine



To determine the association between antenatal corticosteroid treatment and neonatal complications in diabetic mothers delivering after 34 weeks of gestation.


A retrospective cohort study of women with singleton pregnancies diagnosed with gestational diabetes who delivered after 34 weeks of gestation in a university-affiliated medical center (2012–2016). Mothers treated with corticosteroids prior to 34 + 0 weeks of gestation were divided according to gestational age at delivery: late-preterm (34 + 0 to 36 + 6) and term (37 + 0 to 41 + 6). Each group was compared to women delivering at the same gestational age who were not treated with corticosteroids. Primary outcome was defined as a neonatal adverse composite outcome. Birth weight was amongst secondary outcomes measured. Logistic regression analysis was utilized to adjust results to potential confounders.


During the study period, 161 diabetic mothers delivered at late-preterm. Amongst them, 47 (30%) were treated with corticosteroids. 2101 diabetic mothers delivered at term, amongst them 82 (4%) were treated with corticosteroids. Primary outcome did not differ between groups. Multivariate analysis demonstrated that corticosteroid treatment was not associated with neonatal adverse composite outcome when delivery occurred at the late preterm, nor at term (adjusted odds ratio (aOR) = 0.708, 95% CI 0.2–2.3, p = 0.572, and aOR = 1.6, 95% CI 0.2–12.7, p = 0.635, respectively). Birth weight was significantly lower in women treated with corticosteroids (2486 vs. 2675 g, p = 0.02 at late-preterm, and 3160 vs. 3319 g, p < 0.001 at term).


Corticosteroid treatment for diabetic mothers was not associated with neonatal adverse outcomes, but was found associated with a lower birth weight, when delivery occurs after 34 weeks of gestation.


Antenatal corticosteroids Gestational diabetes mellitus Late preterm Term 



Antenatal corticosteroid


Respiratory distress syndrome


Transient tachypnea of the newborn


Gestational diabetes mellitus


Neonatal intensive care unit


Glucose challenge test


Oral glucose tolerance test


Author contributions

EK: protocol development, data analysis and manuscript writing. AH: manuscript writing, data analysis. RC: protocol development and manuscript editing. AW: protocol development and manuscript editing. EH: protocol development and manuscript editing. AB: protocol development, data analysis and manuscript editing.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Human and animal rights statement

This article does not contain any studies with animals performed by any of the authors.


  1. 1.
    American College of Obstetricians and Gynecologists (2016) Periviable birth. Obstetric Care Consensus No. 4. Obstet Gynecol 127:157–169CrossRefGoogle Scholar
  2. 2.
    Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA et al (2011) Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 5 weeks’ gestation. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. JAMA 306:234858CrossRefGoogle Scholar
  3. 3.
    Mori R, Kusuda S, Fujimura M (2011) Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. Neonatal Research Network Japan. J Pediatr 159:110–114CrossRefPubMedGoogle Scholar
  4. 4.
    Chawla S, Natarajan G, Rane S, Thomas R, Cortez J, Lua J (2010) Outcomes of extremely low birth weight infants with varying doses and intervals of antenatal steroid exposure. J Perinat Med 38:419–423CrossRefPubMedGoogle Scholar
  5. 5.
    Chawla S, Bapat R, Pappas A, Bara R, Zidan M, Natarajan G (2013) Neurodevelopmental outcome of extremely premature infants exposed to incomplete, no or complete antenatal steroids. J Matern Fetal Neonatal Med 26:1542–1547CrossRefPubMedGoogle Scholar
  6. 6.
    American College of Obstetricians and Gynecologists (2016) Management of preterm labor. Practice Bulletin No. 171. Obstet Gynecol 128:155–164CrossRefGoogle Scholar
  7. 7.
    Roberts D, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane database of Systematic Reviews 2006, 3Google Scholar
  8. 8.
    Aviram A, Guy L, Ashwal E, Hiersch L, Yogev Y, Hadar E (2016) Pregnancy outcome in pregnancies complicated with gestational diabetes mellitus and late preterm birth. Diabetes Res Clin Pract 113:198–203CrossRefPubMedGoogle Scholar
  9. 9.
    Gewolb IH, O’Brien J (1997) Surfactant secretion by type II pneumocytes is inhibited by high glucose concentrations. Exp Lung Res 23:245–255CrossRefPubMedGoogle Scholar
  10. 10.
    Gewolb IH (1996) Effect of high glucose on fetal lung maturation at different times in gestation. Exp Lung Res 22:201CrossRefPubMedGoogle Scholar
  11. 11.
    Cordero L, Treuer SH, Landon MB, Gabbe SG (1998) Management of infants of diabetic mothers. Arch Pediatr Adolesc Med 152:249–254CrossRefPubMedGoogle Scholar
  12. 12.
    Persson B, Hanson U (1998) Neonatal morbidities in gestational diabetes mellitus. Diabetes Care 21:79–84CrossRefGoogle Scholar
  13. 13.
    Pinter E, Peyman JA, Snow K et al (1991) Effects of maternal diabetes on fetal rat lung ion transport. Contribution of alveolar and bronchiolar epithelial cells to Na+, K(+)-ATPase expression. J Clin Investig 87:821CrossRefPubMedGoogle Scholar
  14. 14.
    Carpenter MW, Coustan DR (1988) Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 144:768–773CrossRefGoogle Scholar
  15. 15.
    Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES (2005) Birth weight standards in the live-born population in Israel. Isr Med Assoc J 7:311–314PubMedGoogle Scholar
  16. 16.
    American College of Obstetricians and Gynecologists (2017) Antenatal corticosteroid therapy for fetal maturation. Committee Opinion No. 713. Obstet Gynecol 130:102–109CrossRefGoogle Scholar
  17. 17.
    Gyamfi Bannerman C, Thom EA, Blackwell SC, Tita TN, Reddy UM, Saade GR et al (2016) Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 374:1311–1320CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR et al (2008) Hyperglycemia and adverse pregnancy outcomes. HAPO Study Cooperative Research Group. N Engl J Med 358:1991–2002CrossRefGoogle Scholar
  19. 19.
    Refuerzo JS, Garg A, Rech B, Ramin SM, Vidaeff A, Blackwell SC (2012) Continuous glucose monitoring in diabetic women following antenatal corticosteroid therapy: a pilot study. Am J Perinatol 29:335–338CrossRefPubMedGoogle Scholar
  20. 20.
    Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley DJ, Spong CY et al (2006) Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network. Am J Obstet Gynecol 195:633–642CrossRefPubMedGoogle Scholar
  21. 21.
    Crowther CA, Haslam RR, Hiller JE, Doyle LW, Robinson JS (2006) Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group. Lancet 367:1913–1919CrossRefPubMedGoogle Scholar
  22. 22.
    Battin M, Bevan C, Harding J (2012) Growth in the neonatal period after repeat courses of antenatal corticosteroids: data from the ACTORDS randomized trial. Arch Dis Child Fetal Neonatal Ed 97:99–105CrossRefGoogle Scholar
  23. 23.
    Espinoza J, Kusanovic JP, Kim CJ, Kim YM, Kim JS, Hassan SS et al (2007) An episode of preterm labor is a risk factor for the birth of a small-for-gestational-age neonate. Am J Obstet Gynecol 196:574PubMedPubMedCentralGoogle Scholar
  24. 24.
    Modanlou HD, Dorchester WL, Thorosian A, Freeman RK (1980) Macrosomia—maternal, fetal and neonatal implications. Obstet Gynecol 55:420–424PubMedGoogle Scholar
  25. 25.
    Spellacy WN, Miller S, Winegar A, Peterson PQ (1985) Macrosomia—maternal characteristics and infant complications. Obstet Gynecol 66:158–161PubMedGoogle Scholar
  26. 26.
    Bérard J, Dufour P, Vinatier D, Subtil D, Vanderstichèle S, Monnier JC et al (1998) Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases > 4500 g. Eur J Obstet Gynecol Reprod Biol 77:51–59CrossRefPubMedGoogle Scholar
  27. 27.
    Lazer S, Biale Y, Mazor M, Lewenthal H, Insler V (1986) Complications associated with the macrosomic fetus. J Repro Med 31:501–505Google Scholar
  28. 28.
    Menticoglou SM, Manning FA, Morrison I, Harman CR (1992) Must macrosomic fetuses be delivered by a cesarean section? A review of outcome for 786 babies ≥ 4,500 g. Aust N Z J Obstet Gynaecol 32:100–103CrossRefPubMedGoogle Scholar
  29. 29.
    Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. N Engl J Med 352:2477–2486CrossRefPubMedGoogle Scholar
  30. 30.
    Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B et al (2009) A multicenter, randomized trial of treatment for mild gestational diabetes. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. N Engl J Med 361:1339–1348CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L (2013) Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med 159:123–129CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyHelen Schneider Hospital for Women, Rabin Medical CenterPetach TikvaIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations